[HTML][HTML] Molecular biology of osteosarcoma

AM Czarnecka, K Synoradzki, W Firlej, E Bartnik… - Cancers, 2020 - mdpi.com
Osteosarcoma (OS) is the most frequent primary bone cancer in children and adolescents
and the third most frequent in adults. Many inherited germline mutations are responsible for …

Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy

MJ Ramaiah, AD Tangutur, RR Manyam - Life sciences, 2021 - Elsevier
The role of genetic and epigenetic factors in tumor initiation and progression is well
documented. Histone deacetylases (HDACs), histone methyl transferases (HMTs), and DNA …

Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy

D Zhi, T Yang, J Yang, S Fu, S Zhang - Acta biomaterialia, 2020 - Elsevier
Among various nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs) have
been increasingly studied for their excellent superparamagnetism, magnetic heating …

Bioinspired adhesive and tumor microenvironment responsive nanoMOFs assembled 3D-printed scaffold for anti-tumor therapy and bone regeneration

Y Jiang, X Pan, M Yao, L Han, X Zhang, Z Jia, J Weng… - Nano Today, 2021 - Elsevier
Tumor-induced bone loss is the main reason causing bone tumor therapy failure. Rational
design of implants with both anti-tumor and bone tissue regeneration functions is urgently …

[HTML][HTML] Mesenchymal stem cell derived exosomes as nanodrug carrier of doxorubicin for targeted osteosarcoma therapy via SDF1-CXCR4 axis

H Wei, F Chen, J Chen, H Lin, S Wang… - International journal …, 2022 - ncbi.nlm.nih.gov
Purpose The objective of this study was to investigate the antitumor activity, targeting
capability, and mechanism of the developed nanodrug consisting of doxorubicin and …

Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study

N Gaspar, R Venkatramani, S Hecker-Nolting… - The Lancet …, 2021 - thelancet.com
Background Tyrosine kinase inhibitors have shown activity in osteosarcoma and might
enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 …

TP53 in bone and soft tissue sarcomas

E Thoenen, A Curl, T Iwakuma - Pharmacology & therapeutics, 2019 - Elsevier
Genomic and functional study of existing and emerging sarcoma targets, such as fusion
proteins, chromosomal aberrations, reduced tumor suppressor activity, and oncogenic …

Chitosan-based biomaterials for the treatment of bone disorders

M Rahimi, SM Mir, R Baghban, G Charmi… - International Journal of …, 2022 - Elsevier
Bone is an alive and dynamic organ that is well-differentiated and originated from
mesenchymal tissues. Bone undergoes continuous remodeling during the lifetime of an …

Controlled delivery of curcumin and vitamin K2 from hydroxyapatite-coated titanium implant for enhanced in vitro chemoprevention, osteogenesis, and in vivo …

N Sarkar, S Bose - ACS applied materials & interfaces, 2020 - ACS Publications
Successful repair of critical-sized tumor-resection defects, especially in load-bearing bones,
still remains a major challenge in clinical orthopedics. Titanium (Ti) implants have been …

[HTML][HTML] The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a …

B Zhang, Y Zhang, R Li, J Li, X Lu, Y Zhang - Journal of Orthopaedic …, 2020 - Springer
Background Osteosarcoma, a primary malignant bone tumor derived from mesenchymal
tissue, is the most common type of pleomorphic tumor that occurs in children and …